Caring for women living with HIV: Gaps in the evidence

Journal of the International AIDS Society

Volumn 16, Issue , 2013, Pages

  Loutfy, Mona R ^a   Sherr, Lorraine ^b   Sonnenberg Schwan, Ulrike ^c   Walmsley, Sharon L ^d   Johnson, Margaret ^e   Monforte, Antonella D'Arminio ^f  

^a UNIVERSITY OF TORONTO   (Canada)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c Working Group Dietetics in Allergy   (Germany)

^d TORONTO GENERAL HOSPITAL   (Canada)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f SAN PAOLO HOSPITAL   (Italy)

Author keywords

Gender; HIV; Pharmacokinetics; Safety; Stigma; Women

Indexed keywords

ANTIRETROVIRUS AGENT;

CARE AND CARING; CARING FOR WOMEN; CLADISTICS; CLINICAL RESEARCH; COMORBIDITY; DEPRESSION; DISEASE COURSE; EMOTIONAL STABILITY; GENETIC VARIABILITY; HEALTH; HEALTH CARE SYSTEM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; IMMUNOLOGICAL PARAMETERS; MEDICAL SUBJECT HEADINGS; MEDLINE; MENOPAUSE; META ANALYSIS (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCTIVE HEALTH; RESERVOIR; REVIEW; SEX DIFFERENCE; SEXUAL HEALTH; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VIRAL TROPISM; VIRUS REPLICATION; WELLBEING;

GENDER; HIV; PHARMACOKINETICS; SAFETY; STIGMA; WOMEN;

ANTI-RETROVIRAL AGENTS; FEMALE; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; MALE; REPRODUCTIVE HEALTH; SEX FACTORS; SOCIOECONOMIC FACTORS;

EID: 84891546396     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.16.1.18509     Document Type: Review

References (126)

1. Jensen SE, Pereira DB, Whitehead N, Buscher I, McCalla J, Andrasik M, et al. Cognitive-behavioral stress management and psychological well-being in HIV+ racial/ethnic minority women with human papillomavirus. Health Psychol. 2013;32(2):227-30.
2. Nicastri E, Leone S, Angeletti C, Palmisano L, Sarmati L, Chiesi A, et al. Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. J Antimicrob Chemother. 2007;60(4):724-32.
3. d'Arminio Monforte A, Gonzalez L, Haberl A, Sherr L, Ssanyu-Sseruma W, Walmsley SL, et al. Better mind the gap: addressing the shortage of HIV-positive women in clinical trials. AIDS. 2010;24(8):1091-4.
4. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19-32.
5. Sayles JN,Wong MD, Kinsler JJ, Martins D, Cunningham WE. The association of stigma with self-reported access to medical care and antiretroviral therapy adherence in persons living with HIV/AIDS. J Gen Intern Med. 2009;24(10): 1101-8.
6. Merkatz RB, Temple R, Subel S, Feiden K, Kessler DA.Women in clinical trials of new drugs. A change in Food and Drug Administration policy. The Working Group on Women in Clinical Trials. N Engl J Med. 1993;329(4):292-6.
7. Heidari S, Eckert MJ, Kippax S, Karim QA, Sow PS, Wainberg MA. Time for gender mainstreaming in editorial policies. J Int AIDS Soc. 2011;14:11.
8. Lawlor DA, Bedford C, Taylor M, Ebrahim S. Geographical variation in cardiovascular disease, risk factors, and their control in older women: British women's heart and health study. J Epidemiol Community Health. 2003;57(2): 134-40.
9. Shaper AG, Pocock SJ, Walker M, Cohen NM, Wale CJ, Thomson AG. British Regional Heart Study: cardiovascular risk factors in middle-aged men in 24 towns. Br Med J (Clin Res Ed). 1981;283(6285):179-86.
10. Heidari S, Abdool Karim Q, Auerbach JD, Buitendijk SE, Cahn P, Curno MJ, et al. Gender-sensitive reporting in medical research. J Int AIDS Soc. 2012; 15(1):11.
11. Editorial. Taking sex into account in medicine. Lancet. 2011;378(9806): 1826.
12. Clark R. Considerations for the antiretroviral management of women in 2008. Womens Health (Lond Engl). 2008;4(5):465-77.
13. Floridia M, Giuliano M, Palmisano L, Vella S. Gender differences in the treatment of HIV infection. Pharmacol Res. 2008;58(3-4):173-82.
14. Ofotokun I, Chuck SK, Hitti JE. Antiretroviral pharmacokinetic profile: a review of sex differences. Gend Med. 2007;4(2):106-19.
15. Sori AT. Poverty, sexual experience and HIV vulnerability risks: evidence from Addis Ababa, Ethiopia. J Biosoc Sci. 2012;44(6):677-701.
16. Raboud J, Blitz S, Antoniou T, Loutfy M, Walmsley S. Recent immigrants show improved clinical outcomes at a tertiary care HIV clinic. Can J Infect Dis Med Microbiol. 2012;23(1):9-14.
17. Gandhi M, Bacchetti P, Miotti P, Quinn TC, Veronese F, Greenblatt RM. Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis. 2002;35(3):313-22.
18. Kuyper LM, Wood E, Montaner JS, Yip B, O'Connell J M, Hogg RS. Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-infected patients in a population-based cohort. J Acquir Immune Defic Syndr. 2004;37(4):1470-6.
19. Collazos J, Asensi V, Carton JA. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART. AIDS. 2007;21(7):835-43.
20. Jarrin I, Geskus R, Bhaskaran K, Prins M, Perez-Hoyos S, Muga R, et al. Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. Am J Epidemiol. 2008;168(5):532-40.
21. Soon GG, Min M, Struble KA, Chan-Tack KM, Hammerstrom T, Qi K, et al. Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000-2008). AIDS Patient Care STDS. 2012;26(8):444-53.
22. Kwakwa H, Spencer D, Evans C, Garner W, Walker I, Temme L. Gender differences in virologic outcomes in a meta-analysis of randomized controlled clinical trials in HIV-1-infected patients on antiretroviral therapy. XIX International AIDS Conference; 2012 Jul 22-27; Washington DC. Abstract THPE041.
23. Burger D, van der Heiden I, la Porte C, van der Ende M, Groeneveld P, Richter C, et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol. 2006;61(2):148-54.
24. Food and Drug Administration. Safety Alert. Videx (didanosine) and Zerit (stavudine) Dear Healthcare Professional Letter [Internet]. 2001. [cited 2013 Feb 1]. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm173947.htm
25. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services [Internet] 2012. [cited 2013 Feb 1]. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/ adultandadolescentgl.pdf
26. Hodder S, Arasteh K, De Wet J, Gathe J, Gold J, Kumar P, et al. Effect of gender and race on the week 48 findings in treatment-naive, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med. 2012;13(7):406-15.
27. Kakuda T, Sekar V, Vis P, Coate B, Ryan R, Anderson D, et al. Pharmacokinetics and Pharmacodynamics of darunavir and etravirine in HIV-1-infected, treatment-experienced patients in the gender, race, and clinical experience (GRACE) trial. AIDS Res Treat. 2012;2012:186987.
28. Loutfy M, la Porte C, Walmsley S, Tseng A, Klein M, Angel J, et al. Antiretroviral pharmacokinetics in HIV-positive women with full virologic suppression on current regimens. 1st International Workshop on HIV & Women, from Adolesence through Menopause; 2011 Jan 10-11; Washington, DC. Abstract O-22.
29. Umeh OC, Currier JS, Park JG, Cramer Y, Hermes AE, Fletcher CV. Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men. J Clin Pharmacol. 2011;51(12):1665-73.
30. Csajka C, Marzolini C, Fattinger K, Decosterd LA, Telenti A, Biollaz J, et al. Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother. 2004;48(9):3226-32.
31. Fletcher CV, Jiang H, Brundage RC, Acosta EP, Haubrich R, Katzenstein D, et al. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J Infect Dis. 2004;189(7):1176-84.
32. Pai MP, Schriever CA, Diaz-Linares M, Novak RM, Rodvold KA. Sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1. Pharmacotherapy. 2004;24(5):592-9.
33. Ribera E, Lopez RM, Diaz M, Pou L, Ruiz L, Falco V, et al. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2004;48(11):4256-62.
34. Trout H, Mentre F, Panhard X, Kodjo A, Escaut L, Pernet P, et al. Enhanced saquinavir exposure in human immunodeficiency virus type 1-infected patients with diarrhea and/or wasting syndrome. Antimicrob Agents Chemother. 2004; 48(2):538-45.
35. Burger DM, Siebers MC, Hugen PW, Aarnoutse RE, Hekster YA, Koopmans PP. Pharmacokinetic variability caused by gender: do women have higher indinavir exposure than men? J Acquir Immune Defic Syndr. 2002;29(1):101-2.
36. von Hentig N, Babacan E, Lennemann T, Knecht G, Carlebach A, Harder S, et al. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. J Antimicrob Chemother. 2008;62(3):579-82.
37. Hoffman RM, Umeh OC, Garris C, Givens N, Currier JS. Evaluation of sex differences of fosamprenavir (with and without ritonavir) in HIV-infected men and women. HIV Clin Trials. 2007;8(6):371-80.
38. Regazzi M, Villani P, Seminari E, Ravasi G, Cusato M, Marubbi F, et al. Sex differences in nevirapine disposition in HIV-infected patients. AIDS. 2003; 17(16):2399-400.
39. Zhou XJ, Sheiner LB, D'Aquila RT, Hughes MD, Hirsch MS, Fischl MA, et al. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Antimicrob Agents Chemother. 1999;43(1):121-8.
40. de Maat MM, Huitema AD, Mulder JW, Meenhorst PL, van Gorp EC, Beijnen JH. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br J Clin Pharmacol. 2002;54(4):378-85.
41. Smith PF, Dicenzo R, Forrest A, Shelton M, Friedland G, Para M, et al. Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. Clin Pharmacokinet. 2005;44(1):99-109.
42. Kakuda TN, Wade JR, Snoeck E, Vis P, Scholler-Gyure M, Peeters MP, et al. Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients. Clin Pharmacol Ther. 2010;88(5):695-703.
43. Anderson PL, Kakuda TN, Kawle S, Fletcher CV. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS. 2003;17(15):2159-68.
44. Bayon C, Robertson K, de Alvaro C, Burgos A, Cabrero E, Norton M, et al. The prevalence of a positive screen for anxiety and/or depressive symptoms in HIV-1+ patients across Western Europe and Canada: the CRANIum Study. 19th Conference on Retroviruses and Opportunistic Infections; 2012 Mar 5-8 Seattle, WA. Abstract #503.
45. Moore RD, Fortgang I, Keruly J, Chaisson RE. Adverse events from drug therapy for human immunodeficiency virus disease. Am J Med. 1996;101(1): 34-40.
46. Clark R. Sex differences in antiretroviral therapy-associated intolerance and adverse events. Drug Saf. 2005;28(12):1075-83.
47. Bonfanti P, Gulisano C, Ricci E, Timillero L, Valsecchi L, Carradori S, et al. Risk factors for lipodystrophy in the CISAI cohort. Biomed Pharmacother. 2003;57(9):422-7.
48. Mazhude C, Jones S, Murad S, Taylor C, Easterbrook P. Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash. AIDS. 2002;16(11):1566-8.
49. Pernerstorfer-Schoen H, Jilma B, Perschler A, Wichlas S, Schindler K, Schindl A, et al. Sex differences in HAART-associated dyslipidaemia. AIDS. 2001; 15(6):725-34.
50. Currier JS, Spino C, Grimes J,Wofsy CB, Katzenstein DA, Hughes MD, et al. Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team. J Acquir Immune Defic Syndr. 2000;24(4):316-24.
51. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG, et al. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet. 2003;361(9359):726-35.
52. Galli M, Ridolfo AL, Adorni F, Gervasoni C, Ravasio L, Corsico L, et al. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr. 2002;29(1):21-31.
53. Agarwal D, Chakravarty J, Chaube L, Rai M, Agrawal NR, Sundar S. High incidence of zidovudine induced anaemia in HIV infected patients in eastern India. Indian J Med Res. 2010;132:386-9.
54. Bersoff-Matcha SJ, Miller WC, Aberg JA, van Der Horst C, Hamrick HJ Jr, Powderly WG, et al. Sex differences in nevirapine rash. Clin Infect Dis. 2001;32(1):124-9.
55. Wamoyi J, Mbonye M, Seeley J, Birungi J, Jaffar S. Changes in sexual desires and behaviours of people living with HIV after initiation of ART: implications for HIV prevention and health promotion. BMC Public Health. 2011;11:633.
56. Spire B, Carrieri P, Garzot MA, L'Henaff M, Obadia Y, Group TRT. Factors associated with efavirenz discontinuation in a large community-based sample of patients. AIDS Care. 2004;16(5):558-64.
57. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131(2):81-7.
58. Currier J, Averitt Bridge D, Hagins D, Zorrilla CD, Feinberg J, Ryan R, et al. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med. 2010;153(6):349-57.
59. Squires KE, Johnson M, Yang R, Uy J, Sheppard L, Absalon J, et al. Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study. J Antimicrob Chemother. 2011;66(2):363-70.
60. Spira S, Wainberg MA, Loemba H, Turner D, Brenner BG. Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother. 2003;51(2):229-40.
61. Lawn SD, Butera ST, Folks TM. Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev. 2001;14(4):753-77.
62. Meier A, Chang JJ, Chan ES, Pollard RB, Sidhu HK, Kulkarni S, et al. Sex differences in the toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med. 2009;15(8):955-9.
63. Poveda E, Briz V, de Mendoza C, Benito JM, Corral A, Zahonero N, et al. Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy. J Med Virol. 2007;79(8): 1040-6.
64. Fantry LE, Zhan M, Taylor GH, Sill AM, Flaws JA. Age of menopause and menopausal symptoms in HIV-infected women. AIDS Patient Care STDS. 2005;19(11):703-11.
65. Tirado G, Jove G, Kumar R, Noel RJ, Reyes E, Sepulveda G, et al. Differential virus evolution in blood and genital tract of HIV-infected females: evidence for the involvement of drug and non-drug resistance-associated mutations. Virology. 2004;324(2):577-86.
66. Taylor S, Davies S. Antiretroviral drug concentrations in the male and female genital tract: implications for the sexual transmission of HIV. Curr Opin HIV AIDS. 2010;5(4):335-43.
67. Schouten J, Wit FW, Stolte IG, van der Valk M, Geerlings SE, de Wolf F, et al. Comorbidity and ageing in HIV-1 infection: the AGEhIV Cohort Study. XIX International AIDS Conference; 2012 Jul 22-27; Washington DC Abstract THAB0205.
68. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53(11):1120-6.
69. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34(6): 831-7.
70. Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr. 2009;52(5):611-22.
71. Fordyce EJ, Wang Z, Kahn AR, Gallagher BK, Merlos I, Ly S, et al. Risk of cancer among women with AIDS in New York City. AIDS Public Policy J. 2000;15(3-4):95-104.
72. Dauby N, De Wit S, Delforge M, Necsoi VC, Clumeck N. Characteristics of non-AIDS-defining malignancies in the HAART era: a clinico-epidemiological study. J Int AIDS Soc. 2011;14:16.
73. Goedert JJ, Schairer C, McNeel TS, Hessol NA, Rabkin CS, Engels EA, et al. Risk of breast, ovary, and uterine corpus cancers among 85,268 women with AIDS. Br J Cancer. 2006;95(5):642-8.
74. Intra M, Gentilini O, Brenelli F, Chagas EM, Veronesi U, Sandri MT. Breast cancer among HIV-infected patients: The experience of the European Institute of Oncology. J Surg Oncol. 2005;91(2):141-2.
75. Shiels MS, Pfeiffer RM, Engels EA. Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med. 2010;153(7):452-60.
76. Palefsky J. Human papillomavirus-related disease in people with HIV. Curr Opin HIV AIDS. 2009;4(1):52-6.
77. Ahdieh-Grant L, Li R, Levine AM, Massad LS, Strickler HD, Minkoff H, et al. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst. 2004;96(14):1070-6.
78. Paramsothy P, Jamieson DJ, Heilig CM, Schuman PC, Klein RS, Shah KV, et al. The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology. Obstet Gynecol. 2009;113(1):26-31.
79. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92(18):1500-10.
80. Heard I. Human papillomavirus, cancer and vaccination. Curr Opin HIV AIDS. 2011;6(4):297-302.
81. Kojic EM, Cespedes M, Umbleja T, Kang M, Aberg J, Allen R, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-positive women. XIX International AIDS Conference; 2012 Jul 22-27; Washington DC. Abstract WEAB0203.
82. Stern Y, McDermott MP, Albert S, Palumbo D, Selnes OA, McArthur J, et al. Factors associated with incident human immunodeficiency virus-dementia. Arch Neurol. 2001;58(3):473-9.
83. McArthur JC. HIV dementia: an evolving disease. J Neuroimmunol. 2004;157(1-2):3-10.
84. Hestad KA, Menon JA, Silalukey-Ngoma M, Franklin Jr DR, Imasiku ML, Kalima K, et al. Sex differences in neuropsychological performance as an effect of human immunodeficiency virus infection: a pilot study in Zambia, Africa. J Nerv Ment Dis. 2012;200(4):336-42.
85. Maki PM, Martin-Thormeyer E. HIV, cognition and women. Neuropsychol Rev. 2009;19(2):204-14.
86. Ettenhofer ML, Hinkin CH, Castellon SA, Durvasula R, Ullman J, Lam M, et al. Aging, neurocognition, and medication adherence in HIV infection. Am J Geriatr Psychiatry. 2009;17(4):281-90.
87. Hinkin CH, Castellon SA, Levine AJ, Barclay TR, Singer EJ. Neurocognition in individuals co-infected with HIV and hepatitis C. J Addict Dis. 2008;27(2): 11-7.
88. Crystal H, Kleyman I, Anastos K, Lazar J, Cohen M, Liu C, et al. Effects of hepatitis C and HIV on cognition in women: data from the Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2012;59(2):149-54.
89. de Pommerol M, Hessamfar M, Lawson-Ayayi S, Neau D, Geffard S, Farbos S, et al. Menopause and HIV infection: age at onset and associated factors, ANRS CO3 Aquitaine cohort. Int J STD AIDS. 2011;22(2):67-72.
90. Cejtin HE, Kalinowski A, Bacchetti P, Taylor RN, Watts DH, Kim S, et al. Effects of human immunodeficiency virus on protracted amenorrhea and ovarian dysfunction. Obstet Gynecol. 2006;108(6):1423-31.
91. Schoenbaum EE, Hartel D, Lo Y, Howard AA, Floris-Moore M, Arnsten JH, et al. HIV infection, drug use, and onset of natural menopause. Clin Infect Dis. 2005;41(10):1517-24.
92. Yin MT, Zhang CA, McMahon DJ, Ferris DC, Irani D, Colon I, et al. Higher rates of bone loss in postmenopausal HIV-infected women: a longitudinal study. J Clin Endocrinol Metab. 2012;97(2):554-62.
93. Miller SA, Santoro N, Lo Y, Howard AA, Arnsten JH, Floris-Moore M, et al. Menopause symptoms in HIV-infected and drug-using women. Menopause. 2005;12(3):348-56.
94. Ferreira CE, Pinto-Neto AM, Conde DM, Costa-Paiva L, Morais SS, Magalhaes J. Menopause symptoms in women infected with HIV: prevalence and associated factors. Gynecol Endocrinol. 2007;23(4):198-205.
95. Clark RA, Mulligan K, Stamenovic E, Chang B, Watts H, Andersen J, et al. Frequency of anovulation and early menopause among women enrolled in selected adult AIDS clinical trials group studies. J Infect Dis. 2001;184(10): 1325-7.
96. Patterson KB, Cohn SE, Uyanik J, Hughes M, Smurzynski M, Eron JJ. Treatment responses in antiretroviral treatment-naive premenopausal and postmenopausal HIV-1-infected women: an analysis from AIDS Clinical Trials Group Studies. Clin Infect Dis. 2009;49(3):473-6.
97. WHO. Sexual health [Internet]. 2011. [cited 2013 Feb 1]. Available from: http://www.who.int/topics/sexual-health/en/
98. WHO/UNFPA. Sexual and reproductive health of women living with HIV/AIDS. Guidelines on care, treatment and support for women living with HIV/AIDS and their children in resource-constrained settings [Internet]. 2006. [cited 2013 Feb 1]. Available from: http://www.unhcr.org/refworld/docid/48abd5960.html
99. Seeley J, Russell S, Khana K, Ezati E, King R, Bunnell R. Sex after ART: sexual partnerships established by HIV-infected persons taking anti-retroviral therapy in Eastern Uganda. Cult Health Sex. 2009;11(7):703-16.
100. Wilson TE, Jean-Louis G, Schwartz R, Golub ET, Cohen MH, Maki P, et al. HIV infection and women's sexual functioning. J Acquir Immune Defic Syndr. 2010;54(4):360-7.
101. Siegel K, Schrimshaw EW, Lekas HM. Diminished sexual activity, interest, and feelings of attractiveness among HIV-infected women in two eras of the AIDS epidemic. Arch Sex Behav. 2006;35(4):437-49.
102. Florence E, Schrooten W, Dreezen C, Gordillo V, Nilsson Schonnesson L, Asboe D, et al. Prevalence and factors associated with sexual dysfunction among HIV-positive women in Europe. AIDS Care. 2004;16(5):550-7.
103. Csete J, Pearshouse R, Symington A. Vertical HIV transmission should be excluded from criminal prosecution. Reprod Health Matters. 2009;17(34): 154-62.
104. Jurgens R, Cohen J, Cameron E, Burris S, Clayton M, Elliott R, et al. Ten reasons to oppose the criminalization of HIV exposure or transmission. Reprod Health Matters. 2009;17(34):163-72.
105. Ahmed A, Hanssens C, Kelly B. Protecting HIV-positive women's human rights: recommendations for the United States National HIV/AIDS Strategy. Reprod Health Matters. 2009;17(34):127-34.
106. Loutfy MR, Sonnenberg-Schwan U, Margolese S, Sherr L, On Behalf of Women For Positive Action. A review of reproductive health research, guidelines and related gaps for women living with HIV. AIDS Care. 2012;25(6): 657-66.
107. Sherr L, Nagra N, Kulubya G, Catalan J, Clucas C, Harding R. HIV infection associated post-traumatic stress disorder and post-traumatic growth - a systematic review. Psychol Health Med. 2011;16(5):612-29.
108. Sherr L, Clucas C, Harding R, Sibley E, Catalan J. HIV and depression - a systematic review of interventions. Psychol Health Med. 2011;16(5):493-527.
109. Clucas C, Sibley E, Harding R, Liu L, Catalan J, Sherr L. A systematic review of interventions for anxiety in people with HIV. Psychol Health Med. 2011; 16(5):528-47.
110. Catalan J, Harding R, Sibley E, Clucas C, Croome N, Sherr L. HIV infection and mental health: suicidal behaviour - systematic review. Psychol Health Med. 2011;16(5):588-611.
111. Machtinger EL, Wilson TC, Haberer JE, Weiss DS. Psychological trauma and PTSD in HIV-positive women: a meta-analysis. AIDS Behav. 2012;16(8): 2091-100.
112. Sherr L, Clucas C, Lampe F, Harding R, Johnson M, Fisher M, et al. Gender and mental health aspects of living with HIV disease and its longer-term outcomes for UK heterosexual patients. Women Health. 2012;52(3):214-33.
113. Vanable PA, Carey MP, Blair DC, Littlewood RA. Impact of HIV-related stigma on health behaviors and psychological adjustment among HIV-positive men and women. AIDS Behav. 2006;10(5):473-82.
114. te Vaarwerk MJ, Gaal EA. Psychological distress and quality of life in drug-using and non-drug-using HIV-infected women. Eur J Public Health. 2001; 11(1):109-15.
115. Joseph EB, Bhatti RS. Psychosocial problems and coping patterns of HIV seropositive wives of men with HIV/AIDS. Soc Work Health Care. 2004;39 (1-2):29-47.
116. Ickovics JR, Milan S, Boland R, Schoenbaum E, Schuman P, Vlahov D, et al. Psychological resources protect health: 5-year survival and immune function among HIV-infected women from four US cities. AIDS. 2006;20(14):1851-60.
117. Whetten K, Reif S, Whetten R, Murphy-McMillan LK. Trauma, mental health, distrust, and stigma among HIV-positive persons: implications for effective care. Psychosom Med. 2008;70(5):531-8.
118. Lechner SC, Antoni MH, Lydston D, LaPerriere A, Ishii M, Devieux J, et al. Cognitive-behavioral interventions improve quality of life in women with AIDS. J Psychosom Res. 2003;54(3):253-61.
119. Lima VD, Geller J, Bangsberg DR, Patterson TL, Daniel M, Kerr T, et al. The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS. 2007; 21(9):1175-83.
120. Turner BJ, Laine C, Cosler L, Hauck WW. Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIVinfected drug users. J Gen Intern Med. 2003;18(4):248-57.
121. Logie CH, James L, Tharao W, Loutfy MR. HIV, gender, race, sexual orientation, and sex work: a qualitative study of intersectional stigma experienced by HIV-positive women in Ontario, Canada. PLoS Med. 2011;8(11):e1001124.
122. Bradford JB, Coleman S, Cunningham W. HIV System navigation: an emerging model to improve HIV care access. AIDS Patient Care STDS. 2007; 21(Suppl 1):S49-58.
123. Naar-King S, Bradford J, Coleman S, Green-Jones M, Cabral H, Tobias C. Retention in care of persons newly diagnosed with HIV: outcomes of the Outreach Initiative. AIDS Patient Care STDS. 2007;21(Suppl 1):S40-8.
124. White RC, Carr R. Homosexuality and HIV/AIDS stigma in Jamaica. Cult Health Sex. 2005;7(4):347-59.
125. Carosi G, Nasta P, Fiore S, Matteelli A, Cauda R, Ferrazzi E, et al. Women facing HIV. Key question on women with HIV infection: Italian consensus workshop. Infection. 2009;37(2):168-78.
126. Wiener LS, Zobel M, Battles H, Ryder C. Transition from a pediatric HIV intramural clinical research program to adolescent and adult community-based care services: assessing transition readiness. Soc Work Health Care. 2007; 46(1):1-19.